ZIVO Bioscience Research and Development Expenses 2016-2024 | ZIVO

ZIVO Bioscience research and development expenses from 2016 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.

ZIVO Bioscience Research and Development Expenses 2016-2024 | ZIVO

ZIVO Bioscience research and development expenses from 2016 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$168.1B
Vertex Pharmaceuticals (VRTX)$119.2B
Regeneron Pharmaceuticals (REGN)$113.7B
Gilead Sciences (GILD)$102.4B
Bristol Myers Squibb (BMY)$101.3B
CSL (CSLLY)$95.4B
GSK (GSK)$84.1B
Alnylam Pharmaceuticals (ALNY)$35B
Argenex SE (ARGX)$32.8B
Biogen (BIIB)$27.5B
BioNTech SE (BNTX)$27.5B
Moderna (MRNA)$24.5B
BeiGene (BGNE)$20.1B
Illumina (ILMN)$20.1B
Genmab (GMAB)$15.8B
BioMarin Pharmaceutical (BMRN)$13.1B
Vaxcyte (PCVX)$12.7B
Exact Sciences (EXAS)$12.5B
Insmed (INSM)$12.5B
Incyte (INCY)$12.2B
Bio-Techne Corp (TECH)$11.9B
Sarepta Therapeutics (SRPT)$11.9B
QIAGEN (QGEN)$10.1B
Bio-Rad Laboratories (BIO.B)$9.1B
Roivant Sciences (ROIV)$8.7B
Ascendis Pharma (ASND)$8.5B
Legend Biotech (LEGN)$7.9B
Intra-Cellular Therapies (ITCI)$7.9B
Repligen (RGEN)$7.8B
Exelixis (EXEL)$7.4B